Table 2. Demographics and clinical characteristics of Crohn’s disease cohorts.
| Partial responder | Full responder | Not on anti-TNF | |
|---|---|---|---|
| n = 5 | n = 5 | n = 4 | |
| Demographics and follow-up | |||
| Age at diagnosis (year) | 12 (10–14) | 12 (9–14) | 15.5 (9–19) |
| Female sex | 40% (2 patients) | 40% (2 patients) | 50% (2 patients) |
| Caucasian | 80% (4 patients) | 80% (4 patients) | 50% (2 patients) |
| African American | 0% (0 patient) | 0% (0 patient) | 0% (0 patient) |
| Native American or Alaskan Native | 0% (0 patient) | 0% (0 patient) | 0% (0 patient) |
| Asian | 0% (0 patient) | 0% (0 patient) | 0% (0 patient) |
| Mixed race | 20% (1 patient) | 0% (0 patient) | 25% (1 patient) |
| Other | 0% (0 patient) | 20% (1 patient) | 0% (0 patient) |
| Disease location/activity | |||
| Location | |||
| L1 | 0% (0 patient) | 0% (0 patient) | 0% (0 patient) |
| L2 | 0% (0 patient) | 0% (0 patient) | 0% (0 patient) |
| L3 | 100% (5 patients) | 100% (5 patients) | 75% (3 patients) |
| P modifier | 20% (1 patient) | 0% (0 patients) | 25% (1 patient) |
| Behavior | |||
| B1 | 100% (5 patients) | 100% (5 patients) | 75% (3 patients) |
| B2 | 0% (0 patients) | 0% (0 patients) | 0% (0 patients) |
| B3 | 0% (0 patients) | 0% (0 patients) | 0% (0 patients) |
| Severity in wPCDAI | 65 (35–77.5) |
65 (22.5–87.5) |
26.3 (15–57.5) |
| Medications | |||
| Mesalamine | 0% (0 patient) | 20% (1 patient) | 50% (2 patients) |
| Azathioprine | 20% (1 patient) | 20% (1 patient) | 25% (1 patient) |
| Methotrexate | 80% (4 patients) | 60% (3 patients) | 0% (0 patient) |
| Anti-TNF | 100% (5 patients) | 100% (5 patients) | 0% (0 patient) |
| Nutritional therapy | 20% (1 patient) | 20% (1 patient) | 25% (1 patient) |
| Steroids | 60% (3 patients) | 60% (3 patients) | 50% (2 patients) |
| Median time since diagnosis | |||
| Median | 31.7 (29.6–37.2) |
36.3 (29.6–37.2) |
32 (24.2–33.7) |